ClinicalTrials.gg
Not yet recruitingNCT07650487Updated Jun 16, 2026

Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study

An observational study in Myocardial Injury and Coronary Artery Disease, sponsored by Second Hospital of Jilin University. Not yet recruiting at 1 site in China. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Second Hospital of Jilin University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
187th of 218
150 · median 720
Started
2026
with 53 others
Observational
219 of 543
82 open now
Primary completion
2027-06
later than 123 of 209 live
Registered
510th of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 187th largest by planned enrollment of the 218 observational ones that give a count, is one of 54 that started in 2026, is one of 219 observational ones, reaches primary completion later than 123 of the 209 other live ones, and was the 510th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

Perioperative myocardial injury (PMI) following coronary artery bypass grafting (CABG) is associated with postoperative morbidity, mortality, and long-term outcomes. High-sensitivity troponin assays and cardiac MRI offer reliable diagnostic tools for PMI, but evidence regarding optimal diagnostic thresholds and perioperative imaging strategy is limited. This prospective clinical study aims to determine the incidence of perioperative myocardial injury using multimodal assessments including high-sensitivity troponin, electrocardiogram, echocardiography, cardiac MRI, and perioperative cardiovascular events.

03

Conditions studied

  • Myocardial Injury
  • Coronary Artery Disease

Keywords

  • Perioperative Myocardial Injury
  • Coronary Artery Bypass Grafting
  • Cardiac MRI
  • hs-Troponin
  • Coronary Artery Disease
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients diagnosed with unstable angina and scheduled to undergo isolated coronary artery bypass grafting (CABG) at the Second Hospital of Jilin University. All participants receive routine perioperative clinical evaluations. The study includes patients aged 21 years or older who provide written informed consent and have had no major cardiovascular events within the previous 6 months. Patients with severe organ dysfunction, pregnancy, or contraindications to cardiac MRI are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 21 years
  2. Undergoing CABG for unstable angina
  3. Able to provide written
  4. No major cardiovascular event in the prior 6 months

Exclusion criteria

Exclusion Criteria:

  1. Significant hepatic, renal, or other major organ dysfunction
  2. Pregnancy or breastfeeding
  3. Withdrawal during the study
  4. to cardiac MRI (metal implants, claustrophobia, etc.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • CABG Patients

    A prospective cohort of adult patients undergoing elective or urgent coronary artery bypass grafting. Participants will undergo perioperative evaluation including hs-troponin testing, ECG, echocardiography, and cardiac MRI to assess perioperative myocardial injury.

    Diagnostic Test: High-Sensitivity Troponin · Diagnostic Test: Cardiac MRI

Interventions

  • Diagnostic testHigh-Sensitivity Troponin

    High-sensitivity troponin levels are measured preoperatively, predischarge, and at 6-month follow-up to assess perioperative myocardial injury.

  • Diagnostic testCardiac MRI

    A diagnostic assessment panel including high-sensitivity troponin testing, electrocardiography, echocardiography, and cardiac magnetic resonance imaging performed during the perioperative period.

06

What researchers measure

Primary outcomes

  1. Incidence of Perioperative Myocardial Injury (PMI)

    Perioperative myocardial injury defined by elevation of high-sensitivity troponin above the 99th percentile upper reference limit together with new myocardial injury detected by cardiac MRI or supportive ECG/echocardiographic changes. PMI is assessed using laboratory testing and imaging performed preoperatively, within 48 hours post-CABG, and at discharge.

    Time frame: Within 48 hours post-CABG

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 11 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650487
Lead sponsor
Second Hospital of Jilin University
Responsible party
Kexiang Liu, MD (Principal Investigator, Second Hospital of Jilin University) — Principal investigator
First posted
Jun 16, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jun 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion